Day Two
The medtech industry, like much of healthcare, has historically been the focus of criticism related to gender imbalance. The underrepresentation of women in the medtech world has led to inequity, with the medical needs of women not receiving the funding and research they deserve, and generic technologies being insufficiently tested on female populations leading to complications. However, there have been some fantastic inroads made in recent years thanks to some excellent initiatives. These inroads will be discussed in depth along with conversations on what more is needed from the sector to ensure women receive proper representation on the medtech stage.
- Role of communities and societies in increasing gender balance
- Next steps in ensuring female representation is here to stay
- Advances in femtech, addressing traditionally female medical needs
- Marissa Fayer - CEO, DeepLook Medical
- Umaima Ahmad - CEO & Co-founder, 52 North Health
- Joana Cartocci - Co-founder & COO, Robeauté
- Jennifer Hoffman - Founder, Unstoppable
Ideas and technology are undoubtedly crucial in bringing a medtech solution to market, however, arguably as important is the leadership team assembled to drive the technology through development and to market. Hear from investors and medtech company CEOs as they discuss why a strong leadership team is so important, and the successful strategies they have seen employed to build the team.
- The value of a strong leadership team when targeting milestones in the journey to commercialisation
- The value of a strong leadership team when investors are doing their due diligence
- Relinquishing the reins, knowing when to look for a new CEO
- The benefit of experienced executives
- Darwin Shurig - CEO & Co-Founder, Shurig Solutions, Inc.
- Gautam Kainth - Partner, TCP Health Ventures
- Zack Lyon - CEO, H3Pelvic
- Nils Bottler - Principal, Angelini Ventures
IP Masterclass - Medtech Focus
- Part 1: Building an Effective IP Portfolio
- Overview from C&R IP experts covering:
- Available forms of protection for Medtech companies including overlooked forms of IP
- IP strategy considerations (budgets, geography, markets, commercial objectives) for start-ups and scale-ups: Allocation of resources and cost-effectiveness
- Specific IP challenges and opportunities facing the Medtech sector
- Options for enforcement of IP in Europe
- Overview from C&R IP experts covering:
- Part 2: Case study
- Part 3 leading into Lunch: Q&A
- Q&A session allowing the opportunity for small-group discussion with C&R IP experts.
- The discussion will break out into different individual topic groups, which participants are free to join.
- Each topic group will pick up a theme from Part 1 of the session, so participants can explore the topic which they feel is most relevant to them.
- Experts from C&R will be available over lunch to continue the discussion with participants, either in small groups or 1-to-1.
Clinical performance studies can signal a pivotal moment in the growth of a medtech startup, proving safety and efficacy whilst providing a springboard to success in the journey to commercialisation. Our panel of medtech leaders discuss winning strategies to get the most out of your clinical trials and to ensure your technology is safe for all.
- Strategies for satisfying the requirements of multiple regulatory boards in a single data set
- The role of vulnerable/underrepresented groups in clinical investigations
- Approaching clinical investigation planning as part of a long-term strategy
- The use of medtech in biotech clinical trials
- Valentina Milanova - Founder & CEO, Daye
- Christopher Allen - Investor, Gilde Healthcare
- Ariana Adjani - Governor at Oxford University Hospitals NHS Foundation Trust & Co-Founder & Managing Director, FINE TREATMENT
- Manu Vohra - Managing Director, Box
In the rapidly evolving Medtech sector, the convergence of microelectronics and microfluidics is unlocking groundbreaking opportunities for diagnostics, therapy, and analysis. Join X-FAB, a global leader in specialty foundry services at the forefront of this transformation, as they explore the pivotal role of CMOS and MEMS technologies in medical product development. X-FAB leverages over 20 years of experience in semiconductor manufacturing to support innovation, reliability, and scalability. By fostering co-development and process customization, X-FAB enables medical device companies to navigate the complexities of supply chains, optimize integration strategies, and accelerate time-to-market.
The benefits of compact, cost-efficient, and high-precision platforms for various diagnosis, and point-of-care applications.
Discover how X-FAB’s standardized process block, silicon and glass substrate proven technologies are paving the way for the next generation of smart medical solutions.
- Oliver Foellmer - Product Marketing Manager, X-Fab MEMS Foundry
Much has been made of the role of artificial intelligence, not just in healthcare but universally across industries. With headlines of virtual doctors and specialists being replaced by machines, it is only natural that AI is generating significant buzz within the space. Though arguably more important than the high-level game changing AI technologies are those not seen by the general public, the uses of AI which can improve workflow and optimise efficiency. Our panel of medtech AI experts and investors discuss the technologies they are most excited about and the future of AI in the medtech industry.
- A holistic view of AI in medtech, and where AI can go in the near future
- Navigating new AI regulatory guidelines
- Patient and general population trust of AI and the impact that has on usage
- Uses of AI as an administrative tool
- James Pink - Senior Director – Medical, Element Materials Technology
- Marina Massingham - Board Member, Aifred Health
- Stephanie Kuku - Chief Knowledge Officer, Conceivable Life Sciences
- James Wong - Ventures Senior Portfolio Manager, Foresight Group
- Jan Beger - Global Head of AI Advocacy, GE HealthCare
- Wim Van Hecke - CEO, icometrix
With the medtech world finding itself in a capital scarce environment much has been made of medtech companies’ ability to diversify revenue streams as an opportunity to generate greater revenue, and also as a way to de-risk potential investment from venture capital companies and strategic partners. This panel of investors and medtech executives discuss the pros and cons of diversified revenue and strategies for entering new markets or therapeutic areas.
- Investor insights into diversified revenue streams
- Ensuring revenue streams are sufficiently aligned
- The danger of spreading resources too thin • Strategies for effective diversification
- Joacim Holter - CEO, Lifecare AS
- Nicholas Ibery - Venture Capital Investor, NLC Ventures
- Lauren Edison - Investment Director, Apposite Capital
- Laurent Pacheco - Investor & Venture Partner, Solas BioVentures
With a new UK government pledging to make Britain a “powerhouse for life sciences and medical technology”, and separate regulations from EU MDR on the way, could the UK soon be the place to be for medtech startups in Europe? Our panel of medtech experts discuss the role of the NHS in the medtech landscape and strategies to maximise the chances of adoption.
- The role of NICE and the NHS Innovation Centre
- Strategies to ensure good market fit
- The role of AI in healthcare systems
- Barriers to adoption
- Konrad Dobschuetz - Former National Director, Former NHS Innovation Accelerator
- Yasemin Arik - Partner, G Square Healthcare Private Equity
- John Milad - CEO, ERS Genomics
- Vladimir Gubala - Chief Scientific Officer & Co-founder, PocDoc
- Matthew Neal - Partner & Head of Life Sciences, 5654 & Company
Universities, particularly in the UK, have established themselves as integral pieces of the medtech landscape. We will discuss the role they play in greater detail, as well as discussing strategies to make the most of the support universities can provide
- The importance of universities in UK medtech innovation
- The role of universities in Europe in protecting innovation
- Strategies to maximise the support offered by university programmes
- Lotus Qi - Head of MedTech, Capital Enterprise
- Daniel Green - Fellow in Entrepreneurship, Imperial College London
- Emilie Syed - Senior Investment Manager, Life Sciences and MedTech, Zinc
- Anne Dobrée - Investment Director, Parkwalk Advisors
- Laurens de Vries - Venture Capital Analyst, Heran Partners